Chicago, ILNCT06477952Now EnrollingIRB Ready

Obstructive Sleep Apnea Clinical Trial in Chicago, IL

Access cutting-edge obstructive sleep apnea treatment through this phase 1/2 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by VA Office of Research and Development

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access obstructive sleep apnea specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related obstructive sleep apnea treatment provided free

Apply for This Chicago Location

Check if you qualify for this obstructive sleep apnea clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Obstructive Sleep Apnea Study in Chicago

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Sponsor: VA Office of Research and Development

Who Can Participate

Inclusion Criteria

Adults 18 to 65 years of age.
AHI 15-50 per hour on pre-treatment polysomnography.

Exclusion Criteria

Positive Airway Pressure (PAP) treatment of OSA: use \> 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data.
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use \> 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report.
History of upper airway surgery for OSA (except adenotonsillectomy).
Central or mixed apneas \>25% of respiratory events on diagnostic polysomnography.
Arterial oxygen saturation \< 75% for \> 5% sleep time on pretreatment polysomnography.
Body mass index \> 45 kg/m2.
If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug.
Active enrollment in a weight loss program.
Shiftwork within 3 months of enrollment.
High-risk occupation: commercial driver and pilot.
Motor vehicle accident or near-miss incident within 1 year of enrollment.
Current drug or habitual alcohol use or positive urine drug screen.
Comorbid medical and psychiatric disorders:
Primary sleep disorders: e.g., narcolepsy, restless legs syndrome.
Uncontrolled mood disorder or a diagnosis of schizophrenia.
Initiation of new antidepressant or antipsychotic medication within 3 months.
Identified as high-risk for suicide in electronic health records.
Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders).
Use of sedative-hypnotic medications within 30 days of enrollment.
Complete blood count or liver function test values more than 1.5 times the upper limit of normal.
Allergy to cannabinoids or sesame oil.
Average weekly alcohol consumption of more than 10 servings.
Participation in other investigational protocols within 30 days of enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06477952) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obstructive Sleep Apnea Treatment Options in Chicago, IL

If you're searching for obstructive sleep apnea treatment options in Chicago, IL, this clinical trial (NCT06477952) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced obstructive sleep apnea specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obstructive sleep apnea clinical trials near you to find additional studies recruiting in your area.

More Lupus Trials in Chicago, IL

See all lupus clinical trials recruiting in Chicago — not just this study.

Browse Lupus Trials in Chicago →

Browse More Trials by Condition

Lupus TrialsUlcerative Colitis TrialsSleep Apnea TrialsPrurigo Nodularis TrialsSystemic Lupus Erythematosus TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL